Molecular, biochemical and clinical aspects of peroxisomes biogenesis disorders
Gootjes, J.

Citation for published version (APA):
Gootjes, J. (2004). Molecular, biochemical and clinical aspects of peroxisomes biogenesis disorders

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: http://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
Chapter 3

Novel mutations in the \textit{PEX2} gene of four unrelated patients with a peroxisome biogenesis disorder

Novel mutations in the PEX2 gene of four unrelated patients with a peroxisome biogenesis disorder

Jeannette Gootjes¹, Orly Elpeleg², François Eyskens³, Hanna Mandel⁴, Delphine Mitanchez⁵, Noboyuki Shimozawa⁶, Yasuyuki Suzuki⁶, Hans R. Waterham¹, and Ronald J.A. Wanders¹

¹Lab. Genetic Metabolic Diseases, Department of Clinical Chemistry and Pediatrics, Emma Children’s Hospital, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands, ²The Metabolic Disease Unit, Shaare-Zedek Medical Center, Jerusalem, Israel ³The University Hospital, Antwerp, Belgium ⁴Metabolic Unit, Department of Pediatrics, Rambam Medical Center, Haifa, Israel ⁵Hôpital Necker-Enfants Malades, Paris, France ⁶Department of Pediatrics, Gifu University School of Medicine, Gifu, Japan.

Summary

The peroxisome biogenesis disorders (PBDs) form a genetically and clinically heterogeneous group of disorders due to defects in at least 11 distinct genes. The prototype of this group of disorders is Zellweger syndrome (ZS) with neonatal adrenoleukodystrophy (NALD) and infantile Refsum disease (IRD) as milder variants. Common to PBDs are liver disease, variable neurodevelopmental delay, retinopathy and perceptive deafness. PBD patients belonging to complementation group 10 (CG10) have mutations in the PEX2 gene (PXMP3), which codes for a protein (PEX2) that contains two transmembrane domains and a zinc-binding domain considered to be important for its interaction with other proteins of the peroxisomal protein import machinery. We report on the identification of four PBD patients belonging to CG10. Sequence analysis of their PEX2 genes revealed 4 different mutations, 3 of which have not been reported before. Two of the patients had homozygous mutations leading to truncated proteins lacking both transmembrane domains and the zinc-binding domain. These mutations correlated well with their severe phenotypes. The third patient had a homozygous mutation leading to the absence of the zinc-binding domain (W223X) and the fourth patient had a homozygous mutation leading to the change of the second cysteine residue of the zinc-binding domain (C247R). Surprisingly, the patient lacking the domain had a mild phenotype, whereas the C247R patient had a severe phenotype. This might be due to an increased instability of PEX2 due to the R for C substitution or to a dominant negative effect on interacting proteins.

Introduction

The peroxisome biogenesis disorders (PBDs; MIM # 601539), which comprise Zellweger syndrome (ZS; MIM # 214100), neonatal adrenoleukodystrophy (NALD; MIM # 202370) and infantile Refsum disease (IRD; MIM # 266510), represent a spectrum of disease severity with ZS being the most, and IRD the least severe disorder. Common to all three PBDs are liver disease, variable neurodevelopmental delay, retinopathy and perceptive deafness.¹ Patients with ZS are severely hypotonic from birth and die before one year of age. Patients with NALD experience neonatal onset of hypotonia and seizures and suffer from progressive white matter disease, dying usually in late infancy.² Patients with IRD
may survive beyond infancy and some may even reach adulthood. Clinical differentiation between these disease states is not very well-defined and patients can have overlapping symptoms.

The absence of functional peroxisomes in patients with a PBD leads to a number of biochemical abnormalities. PBD patients have an impaired synthesis of plasmalogens, due to a deficiency of the two enzymes dihydroxyacetonephosphate acyltransferase (DHAPAT) and alkyl-dihydroxyacetonephosphate synthase. Peroxisomal fatty acid β-oxidation is also defective, leading to the accumulation of very-long chain fatty acids (VLCFAs), notably C26:0, the branched chain fatty acid pristanic acid and the bile acid intermediates di- and trihydroxycholestanolic acid (DHCA and THCA). Phytanic acid α-oxidation and L-pipecolic acid oxidation are also impaired. In contrast, some peroxisomal enzymes show normal activity including catalase, D-amino acid oxidase, L-α-hydroxy acid oxidase A and alanine:glyoxylate aminotransferase, although subcellular fractionation studies have shown that these enzymes are mislocalized in the cytoplasm.

The PBDs are caused by genetic defects in PEX genes encoding proteins called peroxins, which are required for the biogenesis of peroxisomes and function in the assembly of the peroxisomal membrane or in the import of enzymes into the peroxisome. After synthesis on free polyribosomes, peroxisomal matrix proteins carrying either a carboxy-terminal peroxisomal targeting sequence 1 (PTS1) or a cleavable amino-terminal PTS2 signal are translocated across the peroxisomal membrane. A defect in one of the peroxins of the peroxisomal import machinery leads to failure of protein import via the PTS1- and/or PTS2-dependent import pathway, and consequently to functional peroxisome deficiency. Cell fusion complementation studies using patient fibroblasts revealed the existence of at least 11 distinct genetic groups of which currently all corresponding PEX genes have been identified. Most complementation groups are associated with more than one clinical phenotype.

PBD patients belonging to CG10 (CG F according to the Japanese nomenclature) have mutations in the PEX2 gene (PXMP3: MIM # 170993). The PEX2 gene was the first gene found to be mutated in ZS and spans approximately 17.5kb in length and contains four exons. The entire coding sequence is included in exon 4. The gene encodes a 305 amino acid protein (PEX2), with a molecular weight of ~35 kDa. PEX2 is an integral membrane protein with two transmembrane domains, exposing its NH2 and COOH termini to the cytoplasm. PEX2 contains a zinc-binding motif (C3HC4) at the C-terminal part, probably involved in interaction with the other proteins of the peroxisomal protein import machinery. PEX10 and PEX12 also contain similar zinc-binding motifs. PEX2 was shown to interact with PEX10, and was present in a complex consisting of PEX2, PEX5, PEX12 and PEX14.

In this study we report the identification of novel mutations in the PEX2 gene in four PBD patients which, using cell fusion complementation analysis, were shown to belong to complementation group 10. The correlation between genotypes and phenotypes is discussed.
Chapter 3

Methods

Subjects
All patients analyzed showed the clinical characteristics of PBDs. After we obtained informed consent, samples were collected from patients and sent to our laboratory for biochemical and molecular diagnosis. The biochemical diagnosis of a PBD was substantiated by detailed studies in primary skin fibroblasts, which included the following analyses: de novo plasmalogens synthesis, DHAPAT activity, C26:0 and pristanic acid β-oxidation, VLCFA levels, phytanic acid α-oxidation, catalase immunofluorescence and immunoblot analysis of peroxisomal thiolase and acyl-CoA oxidase.15

Case reports
Patient 1 was a male infant, first child of consanguineous Moroccan parents, born after an uneventful pregnancy with low birth weight (2290 g) for gestational age (41 weeks). He was severely hypotonic with absent tendon reflexes and had a large anterior fontanelle and metopic sutures, a high forehead, slight hepatomegaly, cryptorchidism, hypospadia, and a cardiac murmur on auscultation. He was transferred to the neonatal intensive care unit because of generalized convulsions and myoclonic jerks. Neuroimaging of the brain (MRI) showed a complete absence of the corpus callosum, colpocephaly, pachygyria, leukomalacia, and subcortical and periventricular and cerebellar hypoplasia. EEG abnormalities were not specific and showed diffuse epileptic activity. Ocular abnormalities included a pendular nystagmus, cataracts, optic atrophy and a negative visual evoked response (VER). There was an impaired hearing with reduced brainstem auditory evoked potentials (BAEP). There were no skeletal abnormalities. Ultrasonography of the kidneys showed no abnormalities. Cardiac defects included insufficiency of the mitral, tricuspid and aortic valves and a peripheral pulmonary artery stenosis. From the first day he developed a severe icterus with elevated serum liver enzymes (ASAT, ALAT, LDH) and a predominance of serum conjugated bilirubine (cholestasis). A liver biopsy showed severe cholestasis with mitochondrial abnormalities (absence of cristae) on electron microscopy (EM) and absence of peroxisomes and catalase activity present in the cytoplasm of the hepatocytes revealed by immunohistochemical examinations. A skin biopsy showed spicular inclusions in a Schwann cell on EM as has been described in adrenomyeloneuropathy. Biochemical abnormalities included high serum levels of VLCFA, very low plasmalogens content of red blood cell membranes and the presence of THCA and C29 dicarboxylic acid in urine. The course of the disease was rapid: difficulties with sucking and swallowing necessitated gavage feeding; convulsions persisted under therapy with phenobarbital and vigabatrin; the cholestatic icterus worsened with age and his general condition deteriorated progressively. He died at the age of 3 months.

Patient 2 has been described before as the third child of Israeli Arab, 1st degree cousins.16 He was born at term, after an uncomplicated pregnancy and delivery. On routine examination at 9 months of age he was reported as an alert, well developed baby without dysmorphic features, hepatomegaly or neurological abnormalities. At age 22 months he could not walk unassisted, had hypotonia with absent tendon reflexes and atetoid movements. MRI revealed cerebellar and vermal atrophy and dysmyelination. At age 4 years he had retinitis pigmentosa, a flattened electroretinogram, abnormal visual
evoked potentials and sensorineural hearing loss documented by abnormal BAEP. Motor and sensory nerve conduction were prolonged. Results of screening of urine and plasma for abnormal amino acids, organic acids, oligosaccharides and purine and pyrimidine metabolites were negative. Lysosomal enzyme activities in fibroblasts were normal. The patient continued to deteriorate and was in a vegetative state at the age of 9 years. At this age he had elevated plasma levels of VLCFA, pipecolic and phytanic acid and abnormal bile acid intermediates which suggested a peroxisomal biogenesis defect. EM and immunocytochemical studies of the liver disclosed absence of peroxisomes in approximately 90% of hepatocytes. The remaining 10% of the hepatocytes however, had numerous normal looking peroxisomes containing catalase, alanine-glyoxylate aminotransferase and peroxisomal β-oxidation enzymes. At that time, studies performed in cultured fibroblasts revealed normal β-oxidation of VLCFA and normal DHAPAT activity and a normal catalase latency test. The child’s condition continued to deteriorate and he died from pneumonia at age 13 years.

Patient 3 was a female infant, first child of non-consanguineous parents from Ashkenazi-Jewish origin. At birth, she looked dysmorphic with epicanthal folds, broad nasal bridge, high palate, dysplastic ears, excessive skin on the upper back and neck, hypoplastic nipples, hypoplastic external genitalia and hypoplastic nails. She had a broad anterior fontanelle and her liver was enlarged. Her muscle tone was markedly decreased and there was paucity of spontaneous movements. Biochemical investigations in plasma revealed clear abnormalities indicative of a PBD as confirmed in fibroblasts in which a generalized loss of peroxisomal functions and the absence of peroxisomes were found. The patient died in early infancy. The parents had a second child, who was healthy. Their third child was a female, born at 42 weeks. Her physical examination revealed dysmorphism similar to that of her older sister. Echocardiography revealed an atrial septal defect, a ventricular septal defect and tricuspid regurgitation. She was severely hypotonic and unable to suck. Seizures started on the second day of life and continued till her death at one month.

Patient 4 was a full term male of first cousins. He had three healthy sisters. He was delivered after a normal pregnancy by an emergency perpartum caesarian section because of sudden fetal distress. He required immediate mechanical ventilation for the absence of respiratory movements. Generalized seizures were noted soon after birth and treated by intravenous diazepam. The patient was transferred to the intensive care unit. Lethargy, severe hypotonia, poor spontaneous movements and absence of sucking were noted, as well as an unusual large anterior fontanelle. The baby was not dysmorphic. Cardiac and respiratory examination were normal, hemodynamic status was stable and the liver was not enlarged. Initial laboratory investigations were normal. Because of the isolation of Staphylococcus aureus from the mother, neonatal infection was first considered. However, the patient’s neurological status did not improve and the seizures persisted despite the administration of antibiotics and anticonvulsants and the absence of meningitis. Brain MRI examination was normal, excluding severe perinatal asphyxia. Laboratory investigations at 7 weeks of life evidenced moderate cytolysis (ASAT: 246 U/l, ALAT: 88 U/l, γGT: 387 U/l, alkaline phosphatase: 780 U/l). Liver ultrasound examination was normal but renal ultrasound showed two polycystic kidneys. X-ray skeleton was normal. Indirect ophthalmoscopy did not reveal any lesion. In contrast, signal on electroretinogram and visual evoked potentials were absent. Plasma VLCFAs were abnormally elevated
(C24/C22 ratio: 1.76 (N: 0.86 ± 0.07) and C26/C22 ratio: 0.472 (N: 0.026 ± 0.016)). Piperolic acid as well as C27 bile acid intermediates were elevated (piperolic acid: 13.5 μmol/l (N: 0.54-2.46); THCA: 47.5 μmol/l (N < 0.035); DHCA: 61.9 μmol/l (N < 0.119)). These data were indicative of a PBD as confirmed in fibroblasts in which a generalized loss of peroxisomal functions and the absence of peroxisomes were found. Neurological status progressively worsened and the patient died at the age of 2 months.

Biochemical analysis
DHAPAT activity,17 C26:0 and pristanic acid β-oxidation18 were assayed in primary skin fibroblasts as previously described. Catalase immunofluorescence19 and complementation analysis20 were performed as described before. To allow complementation analysis in the cells of patient 2, we cultured these at 40°C for 3 days after fusion of the cells. This treatment results in a significant decrease of catalase-positive particles due to the mosaicism. Details on this method will be described elsewhere (Gootjes et al., Chapter 5).

Mutation analysis
PEX2 mutation analysis in the patients was performed at the genomic DNA level. Genomic DNA was isolated from primary skin fibroblasts using the Wizard genomic DNA purification kit (Promega, Madison, WI). The entire exons plus flanking intron sequences from the PEX2 gene were amplified by PCR using the primer sets shown in table 1. All forward and reverse primers used for mutation analysis were tagged with a -21M13 (5'-TGTAAAACGACGGCCAGT-3') sequence and M13rev (5'-CAGGAAACACGCTATGACC-3') sequence, respectively. PCR fragments were sequenced in two directions using '-21M13' and 'M13rev' fluorescent primers on an Applied Biosystems 277A automated DNA sequencer following the manufacturer's protocol (Perkin Elmer, Wellesley, MA).

<table>
<thead>
<tr>
<th>Primer sets used for PEX2 mutation analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>amplicon</td>
</tr>
<tr>
<td>exon 1</td>
</tr>
<tr>
<td>exon 2</td>
</tr>
<tr>
<td>exon 3</td>
</tr>
<tr>
<td>exon 4a</td>
</tr>
<tr>
<td>exon 4b</td>
</tr>
</tbody>
</table>

Quantitative real-time RT-PCR analysis
Total RNA was isolated from primary skin fibroblasts using Trizol (Invitrogen, Carlsbad, CA) extraction, after which cDNA was prepared using a first strand cDNA synthesis kit for RT-PCR (Roche, Mannheim, Germany). Quantitative real-time PCR analysis of PEX2 and β-2-microglobulin RNA was performed using the LightCycler FastStart DNA Master SYBR green I kit (Roche, Mannheim, Germany). PEX2 primers used were: PEX2-LC-F, 5'-GTCTTCTGACCTTCTGGCAAG-3' and PEX2-LC-R, 5'-AAAATGGAGCCAATAACTAGCTG-3'. β-2-Microglobulin primers used were: b2M-FW, 5'-TGAATTGCTATGCTGCTGGG-3' and b2M-REV, 5'-CATGCTCTCAGCCTTACAAAC-3'. The PCR program comprised a 10 min initial denaturation step at 95°C to activate the hot start polymerase, followed by 40 cycles of 95°C for 10 sec, 58°C for 2 sec and 72°C for 11 sec (9 sec for β-2-microglobulin). Fluorescence was measured at 82°C for PEX2 and 80°C for β-2-microglobulin. Melt curve
Novel mutations in the PEX2 gene

Table 2 PEX2 mutations and biochemical markers in fibroblasts from 4 patients with a PBD

<table>
<thead>
<tr>
<th>ID</th>
<th>Pheno type</th>
<th>Survival</th>
<th>Mutation genomic DNA</th>
<th>Consequence</th>
<th>DHAPAT activity</th>
<th>C26:0 β-oxidation</th>
<th>Pris. acid β-oxidation</th>
<th>Catalase</th>
<th>IF</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>ZS</td>
<td>3 mo</td>
<td>c.739T&gt;C (homo)</td>
<td>C247R</td>
<td>0.7</td>
<td>186</td>
<td>2</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>IRD</td>
<td>13 yrs</td>
<td>c.669G&gt;A (homo)</td>
<td>W223X</td>
<td>7.8</td>
<td>1172</td>
<td>495</td>
<td>+/-</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>ZS</td>
<td>*</td>
<td>c.355C&gt;T (homo)</td>
<td>R119X</td>
<td>0.6</td>
<td>98</td>
<td>41</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>ZS</td>
<td>2 mo</td>
<td>c.279-283delGAGAT(homo)</td>
<td>R94fs, 98X</td>
<td>1.3</td>
<td>78</td>
<td>1</td>
<td>-</td>
<td></td>
</tr>
</tbody>
</table>

Control values

5.8-12.3 1100-1500 675-1100 +

1 nmol/2hr.mg protein 2 pmol/hr.mg protein * early infancy

analysis to show generation of a single product for each reaction was carried out following the PCR program. Amplification of a single product of the correct size was also confirmed by agarose gel electrophoresis. Duplicate analysis was performed for all samples. Data were analyzed using LightCycler Software, version 3.5 (Roche, Mannheim, Germany). To adjust for variations in the amount of input RNA, the values for the PEX2 gene were normalized against the values for the housekeeping gene β-2-microglobulin and the patient ratios were presented as a percentage of the mean of 2 control fibroblast cell lines.

Results

In this study we analyzed four patients affected by a PBD as concluded from the finding of typical abnormalities in plasma (elevated levels of VLCFA, bile acid intermediates, pristanic and phytanic acid) and primary skin fibroblasts (deficient DHAPAT activity, C26:0 β-oxidation and pristanic acid β-oxidation (table 2)). Catalase immunofluorescence revealed the absence of peroxisomes in patient 1, 3 and 4, whereas patient 2 displayed a mosaic pattern, characterized by the absence of punctate immunofluorescence in the majority of cells whereas in about 30% of cells a punctate staining pattern was found. Subsequent cell fusion complementation studies revealed that the four patients belong to CG10 with PEX2 as the causative gene. Sequence analysis of the PEX2 gene of these patients revealed 4 different mutations, 3 of which have not been reported before. The mutations involve one missense mutation, two nonsense mutations and one deletion (table 2). Patient 1 was homozygous for a missense mutation changing the cysteine at position 247 to an arginine (figure 1). This cysteine residue is the second cysteine residue of the

![Figure 1](image_url)

**Figure 1** Deduced PEX2 products of 4 PBD patients. The diagram shows the predicted protein product of each PEX2 allele. The zinc-binding domain is indicated by a dark gray box and each of the transmembrane domains is indicated by the black boxes. The light gray bar indicates the length of additional amino acids that are appended as a result of a frameshifting mutation.
zinc-binding domain. Patient 2 was homozygous for a nonsense mutation (W223X) that truncates the protein between the second transmembrane domain and the zinc-binding domain. Patient 3 was homozygous for a nonsense mutation (R119X) that truncates the protein before the first transmembrane domain. This mutation has been described before.\textsuperscript{10,21} Patient 4 was homozygous for a 5-bp deletion (279-283delGAGAT) that results in a frameshift and leads to truncation of the protein before the first transmembrane domain. Thus, three of the four mutations create an early termination codon in the PEX2 open reading frame that will result in a truncated protein product (figure 1).

In eukaryotic cells, the introduction of a nonsense codon into mRNA can also lead to nonsense-mediated decay of the mRNA, resulting in a reduction of protein production, a process common in human genetic disease.\textsuperscript{22,23} To test for this latter possibility as a primary cause of PEX2 dysfunction in these patients, RNA from the patient cell lines was analyzed by real-time RT-PCR to quantify PEX2 mRNA. These analyses showed that PEX2 transcript levels in patient 1, carrying the missense mutation C247R, were elevated 150%, compared to controls (figure 2). Of the three patients with frameshift or nonsense mutations, only patient 2 showed decreased PEX2 mRNA levels of around 35%. The PEX2 transcript levels in patient 3 and 4 were relatively normal with 90% and 80%, respectively.

|-----------|-----------|-----------------|-----------------|-----------------|-----------------|

**Figure 2** Quantitative real-time RT-PCR analysis of PEX2. Presented are the PEX2/β-2-microglobulin ratios expressed as percentages of the mean of controls 1 and 2.

**Discussion**

Mutations in PEX2 are known to underlie the disease in patients with a PBD belonging to complementation group 10.\textsuperscript{10} In this study we determined the PEX2 genotypes of four patients diagnosed in our laboratory. All four patients have mutations in the PEX2 gene, confirming that a defective PEX2 is responsible for the disease in these patients. The mutations involve one missense mutation, two nonsense mutations and one deletion. Three of the mutations have not been described previously. Except for patient 2, all patients had the severe ZS phenotype and died before 3 months of age. Patient 2 was diagnosed with IRD and survived for over 9 years. For patient 3 and 4 the phenotype appears to correlate rather well with the genotype. The two mutations in both patients involve a stop codon upstream of the sequences encoding the transmembrane domains and result into a severe ZS phenotype. This strongly suggests that either no functional PEX2 protein is produced or that the truncated proteins are not correctly localized to the peroxisomal membrane. The mutation in patient 3 has been described before in homozygous\textsuperscript{10} and compound heterozygous form.\textsuperscript{24,25} Both homozygous patients
described presented with the ZS phenotype. In one compound heterozygous patient the
mutation was found in combination with a temperature-sensitive missense mutation
(E55K), which led to a milder phenotype, whereas in another patient it was found in
combination with an R125X mutation on the other allele. This patient was diagnosed with
the severe ZS phenotype and died before 3 months of age. In addition to this, one more
patient was described lacking (one of) the transmembrane domains. This patient was
homozygous for a del550C mutation, leading to a frameshift at amino acid 184 and
termination seven amino acids downstream. The predicted protein sequence lacks both
the second transmembrane domain and the zinc-binding domain and results in the ZS
phenotype. These additional cases support our conclusions on patient 3 and 4.

Biochemical data are in agreement with the genotype in patients 3 and 4: DHAPAT
activity, C26:0 β-oxidation and pristanic acid β-oxidation are clearly abnormal. Recent
studies in fibroblasts of patients suffering from severe and mild forms of PBD have shown
that DHAPAT activity, C26:0 β-oxidation and, to a lesser extent, pristanic acid β-oxidation
correlate best with patients’ survival.

The mutation found in patient 2 is predicted to result in a protein that lacks the zinc-
binding domain but does contain the two transmembrane domains. This patient was
described before as a patient with a ‘new type of peroxisomal disorder with variable
expression in liver and fibroblasts’. When examined at 9 months of age, no major
abnormalities were found but after the first year of life neurodegenerative symptoms
developed and at the age of 9 he was in a vegetative state. The patient died from
pneumonia at the age of 13 years. Previous studies in fibroblasts of this patient did not
reveal peroxisomal abnormalities with regard to de novo plasmalogensynthesis, DHAPAT
activity and the presence of catalase in a particle bound form. However, these studies were
done in the beginning of the 1990s, and since then more sensitive methods to assess
peroxisomal functioning have been developed including immunofluorescence microscopy
analysis using antibodies raised against catalase as well as the measurements of C26:0 and
pristanic acid β-oxidation. When we reinvestigated the patient’s fibroblasts using these
methods we found clear abnormalities such as a reduced rate of pristanic acid β-oxidation
and an abnormal catalase immunofluorescence pattern with both positive and negative
cells (table 2). This mosaic pattern is indicative of a peroxisomal biogenesis defect.
Biochemical parameters such as VLCFA, phytanic acid and DHCA and THCA levels were
also abnormal in plasma of the patient. In liver, catalase was localized in only 10% of
peroxisomes. Although PEX2 RNA levels were decreased to 35%, in part of the
fibroblasts peroxisomes were normally present. This suggests that the truncated form of
PEX2 lacking the zinc-binding domain that is present may be localized correctly and is still
(partly) active. This would imply that the zinc-binding domain is not obligatory for the
activity of PEX2. A similar phenomenon was described before in another PEX2-deficient
patient that had a deletion (642delG) leading to a frameshift at amino acid 214 leading to
termination two amino acids downstream. This patient was diagnosed also with a mild
phenotype (IRD). In this patient only fibroblasts were studied, which also showed a
mosaic pattern of catalase staining (20% of the cells contained normal peroxisomes), and
mildly reduced VLCFA β-oxidation and normal DHAPAT activity. It can be concluded
from both our patient as well as the patient reported by Shimozawa et al., 2000, that
truncated PEX2 lacking the zinc-binding domain still displays some functional activity.
The mutation found in patient 1, which changes the second cysteine residue (position 247) of the zinc-binding domain into arginine, however, seems to disagree with this postulate. This patient displays a severe phenotype and severely impaired biochemical parameters, indicative of a severe impairment in peroxisome biogenesis. A comparable mutation was found in a CHO-mutant (C246Y; the CHO PEX2 comprises 304 amino acids, one residue shorter than human PEX2), which also did not show any catalase positive particles. Apparently, the complete absence of the zinc-binding domain is less deleterious for the functioning of PEX2, than a mutation within the domain itself. Because PEX2 RNA transcript levels in this patient were normal, this may be due to an increased instability of PEX2 protein due to this mutation. Unfortunately, no antibodies raised against full length PEX2 are available to study this possibility. Alternatively, it may be that the mutation in the zinc-binding domain, which is thought to function in the interaction with other proteins (for instance PEX10), causes an inhibiting effect on the function of these other proteins, thereby causing a severe impairment of peroxisome biogenesis. Such a 'dominant negative' effect is not present in patients completely lacking the zinc-binding domain. CHO cell lines with missense mutations of two other cysteine residues in the zinc-binding domain have also been reported. A C258Y mutation has been described, which leads to a disturbed import of PTS1 proteins, whereas the PTS2 protein peroxisomal thiolase is normally imported. A CHO mutant with a C264S mutation was found to have a normal catalase import. Thus, not all cysteine mutations in this region lead to a severe defect.

Mutations in the other two zinc-binding domain-containing peroxins PEX10 and PEX12 have also been reported. In PEX10, one mutation leads to truncated PEX10 lacking the zinc-binding domain. All patients homozygous for this mutation were diagnosed with the severe ZS phenotype. Moreover, all patients lacking the zinc-binding domain of PEX12 display a severe clinical phenotype and abnormal biochemical parameters, suggesting that in PEX12 the zinc-binding domain is indispensable for its function. Thus, regarding the zinc-binding domain, the genotype-phenotype correlation for PEX2 seems to be different than for other proteins, making the function of this domain in PEX2 unclear, and worthwhile to study in more detail.

Acknowledgements

The authors thank Petra Mooijer and Conny Dekker for biochemical analyses in patient fibroblasts. Dr. Deprettere is gratefully acknowledged for his help in the diagnosis of one of the patients.

References

Novel mutations in the PEX2 gene


